Jefferies Financial Group Inc. Makes New $1.96 Million Investment in Medpace Holdings, Inc. $MEDP

Jefferies Financial Group Inc. bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 3,700 shares of the company’s stock, valued at approximately $1,959,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. NewEdge Advisors LLC increased its holdings in shares of Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after buying an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after acquiring an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Sivia Capital Partners LLC bought a new position in Medpace in the 2nd quarter valued at $296,000. Finally, M&T Bank Corp raised its position in Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after purchasing an additional 31 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Stock Down 1.8%

MEDP stock opened at $600.65 on Friday. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The company has a market cap of $16.77 billion, a P/E ratio of 35.21, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15. The business’s fifty day moving average is $565.33 and its 200-day moving average is $494.55.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other news, Director Robert O. Kraft sold 3,858 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $617.81, for a total value of $2,383,510.98. Following the completion of the transaction, the director owned 955 shares of the company’s stock, valued at $590,008.55. The trade was a 80.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO August J. Troendle sold 4,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $620.03, for a total transaction of $2,480,120.00. Following the completion of the sale, the chief executive officer owned 540,544 shares of the company’s stock, valued at approximately $335,153,496.32. This represents a 0.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 133,821 shares of company stock valued at $81,748,135. Corporate insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Leerink Partners set a $620.00 target price on Medpace in a report on Thursday, July 23rd. Mizuho upped their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Truist Financial increased their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Finally, BMO Capital Markets boosted their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, Medpace currently has a consensus rating of “Hold” and an average price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.